


Claim listing

1. (Currently amended) A cis-stilbene of the formula



Wherein ~~wherein~~:


R¹, R² and R³ are each independently alkyl,
R⁴ is alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo,

R⁵ is hydrogen, alkoxy, alkyl, alkylthio, hydroxy or halo,
or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.

2. (Original) A cis-stilbene according to claim 1 wherein R¹, R² and R³ are all methyl.
3. (Original) A cis-stilbene according to claim 1 wherein R⁵ is hydrogen and R⁴ is alkyl or halo.
- 4 (Original) (Z)-1-(3-hydroxy-4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene.
5. (Currently amended) A prodrug of a cis-stilbene which is a carboxylate ester, phosphate ester, sulphate ester or carbonate of the cis-stilbene as claimed in claim 1.
6. (Original) A prodrug of a cis-stilbene which is a phosphate ester of a cis-stilbene according to claim 1.
- 7 (Original) A prodrug according to claim 5 which is a dihydrogen phosphate ester.
- 8 (Original) (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethynyl]phenyl dihydrogen phosphate.
- 9 (Currently amended) A composition for use in the ~~treatment~~ destruction of ~~neovascularisation~~ neovasculature which composition contains an ~~effective~~ amount of the cis-stilbene according to claim 1 effective to destroy neovasculature and a pharmaceutically acceptable excipient.
- 10 (Currently amended) A method for treating neovascularisation in a patient comprising ~~preparing a~~ administering to a patient suffering from ~~neovascularisation a therapeutically effective amount of a~~

- composition ~~for the treatment of neovascularisation~~ comprising with the cis-stilbene as claimed in claim 1.
- 11 (Currently amended) A prodrug of a cis-stilbene which is ~~a~~ an carboxylate ester, phosphate ester, sulphate ester or carbonate of the cis-stilbene as claimed in claim 2.
- 12 (Currently amended) A prodrug of a cis-stilbene which is ~~a~~ an carboxylate ester, phosphate ester, sulphate ester or carbonate of the cis-stilbene as claimed in claim 3.
- 13 (Currently amended) A composition for use in the ~~treatment~~ destruction of ~~neovascularisation~~ neovasculature which composition contains an ~~effective~~ amount of the prodrug according to claim 5 effective to destroy neovasculature and a pharmaceutically acceptable excipient.
- 14 (Currently amended) A method for treating neovascularisation in a patient comprising ~~preparing a~~ administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition ~~for the treatment of neovascularisation~~ comprising with the prodrug as claimed in claim 5.
- 15 (Cancelled)
- 16 (Cancelled)
- 17 (Cancelled)
- 18 (New) A composition for use in the destruction of neovasculature which composition contains an amount of a compound according to claim 2 effective to destroy neovasculature and a pharmaceutically acceptable excipient:
- 19.(New) A composition for use in the destruction of neovasculature which composition contains an amount of a compound according to claim 3 effective to destroy neovasculature and a pharmaceutically acceptable excipient.
- 20 (New) A composition for use in the destruction of neovasculature which composition contains an amount of (Z)-1-(3-hydroxy-4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene or a prodrug thereof effective to destroy neovasculature and a pharmaceutically acceptable excipient.

21. (New) A cis-stilbene prodrug of formula



wherein:

- R^1 , R^2 and R^3 are each independently alkyl,
 R^4 is alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo,
 R^5 is hydrogen, alkoxy, alkyl, alkylthio, hydroxyl or halo, and
 X is a group which can be removed in vivo by hydrolysis.

22.(New) A cis-stilbene prodrug according to claim 21 wherein:

R^1 , R^2 and R^3 are all methyl.

23. (New) A cis-stilbene prodrug according to claim 22 wherein:

R^5 is hydrogen and R^4 is alkyl or halo.

24.(New) A cis-stilbene prodrug according to claim 23 wherein R^4 is methyl.

25. (New) A cis-stilbene prodrug according to claim 21 which is a carboxylic ester, phosphate ester, sulphate ester or carbonate.

26.(New) A cis-stilbene prodrug according to claim 21 which is a phosphate ester.

27.(New) A prodrug according to claim 25 which is a dihydrogen phosphate ester.

28. (New) (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate.

29.(New) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 21 and a pharmaceutically acceptable excipient.

30. (New) A composition as claimed in claim 29 in combination with at least one further anti-tumour substance.

31. (New) A cis-stilbene prodrug according to claim 22 which is a carboxylic ester, phosphate ester, sulphate ester or carbonate.

32. (New) A cis-stilbene prodrug according to claim 23 which is a carboxylic ester, phosphate ester, sulphate ester or carbonate.

33. (New) A composition for use in the destruction of neovasculature which composition contains an effective amount of the prodrug according to claim 25 and a pharmaceutically acceptable excipient.
34. (New) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 26 and a pharmaceutically acceptable excipient.
35. (New) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 27 and a pharmaceutically acceptable excipient.
36. (New) A composition for use in the destruction of neovasculature composition contains an effective amount of the cis-stilbene dihydrogen phosphate according to claim 28 and a pharmaceutically acceptable excipient.
37. (New) A method of treatment of a disease involving neovascularisation comprising the administration of an effective amount of a cis-stilbene prodrug as claimed in claim 21.
38. (New) A method according to claim 37 wherein the disease is cancer involving a solid tumour.
39. (New) A method according to claim 38 wherein said cis-stilbene prodrug is administered in combination with radiotherapy or another anti-tumor substance.
40. (New) A method according to claim 37 wherein the disease is a disease of the eye.
41. (New) A method according to claim 37 wherein the cis-stilbene prodrug is (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate.
42. (New) A method of treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising a compound according to claim 4.
43. (New) A method of treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising a dihydrogen phosphate ester of a compound according to claim 4.
44. (New) A method according to claim 42 wherein neovascularisation of the eye is treated.
45. (New) A method according to claim 43 wherein neovascularisation of the eye is treated.